FunPep

Executive Summary

FunPep is a Japanese biotech company leveraging its functional peptide technology platform to develop innovative therapeutics for dermatology, immunology, and infectious diseases. Founded in 2020 and headquartered in Tokyo, the company focuses on synthetic peptides with specific biological activities, targeting skin ulcer treatment and antibody-inducing vaccines. Their lead candidate, SR-0379, is a multifunctional peptide with both angiogenic and antimicrobial properties, currently in Phase III trials for chronic skin ulcers. With a lean team of 10-50 employees, FunPep represents a focused player in the peptide therapeutics space, addressing significant unmet needs in wound healing and infection prevention. SR-0379's Phase III progress is the company's primary value driver. The candidate's unique dual mechanism of action—promoting angiogenesis and providing antimicrobial activity—positions it as a potential best-in-class treatment for difficult-to-heal wounds, such as diabetic ulcers and pressure sores. While FunPep has not disclosed total funding or valuation, its private status and early-stage pipeline imply higher risk. However, the Phase III stage suggests some de-risking. Upcoming catalysts include final Phase III data readout and potential regulatory submissions in Japan and possibly other markets. The company may also seek strategic partnerships for commercialization.

Upcoming Catalysts (preview)

• Q4 2026Phase III Top-Line Data for SR-0379 (Skin Ulcers)65% success